Birmingham Psychiatry Pharmaceutical Studies, Inc.

Birmingham, Alabama 35226

0 studies enrolling now · 11 studies all time

What they study most

Bipolar I Depression, Depression, Major Depressive Disorder, Major Depressive Disorder With Mixed Features, Schizophrenia

Studies at this site

• An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia — Stopped early
• Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose — Completed
• Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder — Completed
• Major Depressive Disorder With Mixed Features - Extension — Completed
• Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Stopped early
• Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder — Completed
• Switching to Iloperidone From Other Antipsychotics in Schizophrenia — Completed
• Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364) — Completed
• A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression — Completed
• Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia — Completed